

OMTN, Volume 12


Supplemental Information

Long-Term Morpholino Oligomers in Hexose Elicits Long-Lasting Therapeutic Improvements in *mdx* Mice

Gang Han, Caorui Lin, Hanhan Ning, Xianjun Gao, and HaiFang Yin

Supplementary Figures


Supplementary Figure 1



Supplementary Figure 1. Examination of body-weight and pathophysiological changes of *mdx* mice treated with PMO-GF for one year. (A) Measurement on body-weight of *mdx* mice treated with PMO-GF during the one-year time course. **(B)** H&E staining of kidney (upper panel) and liver (lower panel) tissues sections from *mdx* mice treated with PMO-GF, untreated *mdx* and *C57BL6* controls (scale bar = 200 μ m). **(C)** H&E staining of body-wide peripheral muscle tissue sections from *mdx* mice


treated with PMO-GF, untreated *mdx* and *C57BL6* controls (scale bar = 200 μm). (D) Detection of CD68⁺ macrophage in the diaphragms and quadriceps of treated and untreated *mdx* mice (scale bar = 100 μm). Arrows indicate macrophages detected by CD68⁺ mouse monoclonal antibody.

Supplementary Figure 2



Supplementary Figure 2. Transmission electron microscopy micrographs of the the intermyofibrillar mitochondria (IFM) pool density in *mdx* mice treated with PMO-GF for one year (scale bar=2 μm). The arrowhead points to the IFM.

Supplementary Figure 3



Supplementary Figure 3. Measurement of serum creatine kinase-MB (CK-MB) and membrane integrity in heart from *mdx* mice treated with PMO-GF for one year. **(A)** Measurement of serum creatine kinase-MB (CK-MB) levels. **(B)** IgG staining to assess the membrane integrity in heart from *mdx* mice treated with PMO-GF, untreated age-matched *mdx* and *C57BL6* controls (scale bar=200 μ m).